85 related articles for article (PubMed ID: 31461081)
1. Association between HNF4A mutations and bleeding complications in patients with stable international normalized ratio.
Kim W; Yee J; Chang BC; Chung JE; Lee KE; Gwak HS
Pharmacogenet Genomics; 2019 Oct; 29(8):200-206. PubMed ID: 31461081
[TBL] [Abstract][Full Text] [Related]
2. Effects of Polymorphisms in Myc-Related Genes on Bleeding Complications in Patients with Stable Warfarin Responses.
Yee J; Kim W; Chang BC; Chung JE; Lee KE; Gwak HS
Cardiovasc Ther; 2019; 2019():1813747. PubMed ID: 31772606
[TBL] [Abstract][Full Text] [Related]
3. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
An SH; Lee KE; Chang BC; Gwak HS
J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
[TBL] [Abstract][Full Text] [Related]
4. Genetic variations in the transcription factors
Yee J; Kim W; Chang BC; Chung JE; Lee KE; Gwak HS
Drug Des Devel Ther; 2019; 13():1717-1727. PubMed ID: 31190750
[No Abstract] [Full Text] [Related]
5. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
An SH; Chang BC; Lee KE; Gwak HS
Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
[TBL] [Abstract][Full Text] [Related]
6. TGF-β1 polymorphism increases the risk of bleeding complications in patients on oral anticoagulant after cardiac valve replacement.
Kim W; Yee J; Chang BC; Chung JE; Lee KE; Gwak HS
Heart Vessels; 2021 Dec; 36(12):1885-1891. PubMed ID: 33983456
[TBL] [Abstract][Full Text] [Related]
7. Association between
Yee J; Kim W; Chang BC; Chung JE; Lee KE; Gwak HS
Pharmacogenomics; 2019 Jun; 20(9):659-667. PubMed ID: 31068094
[No Abstract] [Full Text] [Related]
8. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
9. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
[TBL] [Abstract][Full Text] [Related]
10. Mutations in CYP2C9 and/or VKORC1 haplotype are associated with higher bleeding complications in patients with Budd-Chiari syndrome on warfarin.
Shukla A; Jain A; Kahalekar V; Bendkhale S; Gogtay N; Thatte U; Bhatia S
Hepatol Int; 2019 Mar; 13(2):214-221. PubMed ID: 30617764
[TBL] [Abstract][Full Text] [Related]
11. Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study.
Sridharan K; Modi T; Bendkhale S; Kulkarni D; Gogtay NJ; Thatte UM
Curr Clin Pharmacol; 2016; 11(1):62-8. PubMed ID: 26777610
[TBL] [Abstract][Full Text] [Related]
12. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
[TBL] [Abstract][Full Text] [Related]
13. Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR).
Pourgholi L; Goodarzynejad H; Mandegary A; Ziaee S; Talasaz AH; Jalali A; Boroumand M
Toxicol Appl Pharmacol; 2016 Oct; 309():37-43. PubMed ID: 27581200
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
[TBL] [Abstract][Full Text] [Related]
15. VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy.
Mandic D; Bozina N; Mandic S; Samardzija M; Milostic-Srb A; Rumora L
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):905-13. PubMed ID: 26445138
[TBL] [Abstract][Full Text] [Related]
16. Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements.
Zhou L; Ding Y; Gao Y; Yang B; Bao J; Ma J
Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):1-9. PubMed ID: 31914334
[No Abstract] [Full Text] [Related]
17. Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves.
Lee KE; Chung JE; Yi B; Cho YJ; Kim HJ; Lee GY; Kim JH; Chang BC; Gwak HS
Int J Cardiol; 2017 Jun; 236():393-397. PubMed ID: 28262345
[TBL] [Abstract][Full Text] [Related]
18. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
19. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
[TBL] [Abstract][Full Text] [Related]
20. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
Zhuang W; Wu D; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
